| Followers | 10 |
| Posts | 1467 |
| Boards Moderated | 0 |
| Alias Born | 07/16/2006 |
Monday, October 06, 2014 5:34:29 PM
No News is good news:
Day -2. This is the day NNVC shipped 200g to BASi. So today’s news was good news. This will be a reversal of the theme that we will be following for the next few weeks.
Day 0. A no News day! This is an assumption that the drug was received by the Lab. How many animals are going to be used in the trials? Was the drug deliverer on time? Who was the courier?
Day 1. Another “No News Is Good News Day”. How many and what species of animals are going to get an infusion today? Because of the importance of this trial let me assume this is the first day an animal or animals were treated? These are, I assume, healthy animals that are the guinea pigs for Flucide. This will be the real first day of testing Flucide. The vitals are taken as a baseline.
Day 2. The cides have been working for 24 hours now. In case you’re a new reader of NNVC the Nanoviruscides start working the second they are infused into the blood stream. The agnostic particles begin searching out cides when mixed with the patient’s blood. When the infusion is completed the circulation system has mixed the cides fairly equally throughout a body. Any virus organism that contacts the cide in the proper manner is enveloped and the disassembly begins. This organism is no longer a threat to the rest of the body as each union of cide and virus organism reduces the viral load. The system will eliminate the spent cide and disassembled virus organism thru the kidneys.
Information on the mechanism of action has not been disseminated in the materials I have read. Is there heat released when the coupling and disassembling happens? If so there will be a rise in body temperature commiserate with the amount of action caused by the cide’s successful action. Since this is a toxicity determining trial, assuming healthy subjects without any viruses circulating in their blood stream, we can assume that the temperature of the subjects will remain unchanged.
Writers note: When the cide is infused into an infected blood stream the body will already have had a temperature increase. Will the cide’s action increase the blood temperature? If so how much? If the temperature is at a critical level already then the rate of infusion needs to be carefully planned. The body is hard at work trying to make and rid itself of the virus. The cide is only an aid to the naturally occurring disease fighting mechanism of the body. As the cide particles are infused and reduce the viral load the body’s temperature may not be reduced immediately because the body is working hard to overcome the viral load. Depending on the disease’s progression this make take a while. I dislike such inexact terms like “awhile”. Does this mean 1 day or several hours? ( I am on vacation, more to follow in the next few days, stay tuned!)
Day -2. This is the day NNVC shipped 200g to BASi. So today’s news was good news. This will be a reversal of the theme that we will be following for the next few weeks.
Day 0. A no News day! This is an assumption that the drug was received by the Lab. How many animals are going to be used in the trials? Was the drug deliverer on time? Who was the courier?
Day 1. Another “No News Is Good News Day”. How many and what species of animals are going to get an infusion today? Because of the importance of this trial let me assume this is the first day an animal or animals were treated? These are, I assume, healthy animals that are the guinea pigs for Flucide. This will be the real first day of testing Flucide. The vitals are taken as a baseline.
Day 2. The cides have been working for 24 hours now. In case you’re a new reader of NNVC the Nanoviruscides start working the second they are infused into the blood stream. The agnostic particles begin searching out cides when mixed with the patient’s blood. When the infusion is completed the circulation system has mixed the cides fairly equally throughout a body. Any virus organism that contacts the cide in the proper manner is enveloped and the disassembly begins. This organism is no longer a threat to the rest of the body as each union of cide and virus organism reduces the viral load. The system will eliminate the spent cide and disassembled virus organism thru the kidneys.
Information on the mechanism of action has not been disseminated in the materials I have read. Is there heat released when the coupling and disassembling happens? If so there will be a rise in body temperature commiserate with the amount of action caused by the cide’s successful action. Since this is a toxicity determining trial, assuming healthy subjects without any viruses circulating in their blood stream, we can assume that the temperature of the subjects will remain unchanged.
Writers note: When the cide is infused into an infected blood stream the body will already have had a temperature increase. Will the cide’s action increase the blood temperature? If so how much? If the temperature is at a critical level already then the rate of infusion needs to be carefully planned. The body is hard at work trying to make and rid itself of the virus. The cide is only an aid to the naturally occurring disease fighting mechanism of the body. As the cide particles are infused and reduce the viral load the body’s temperature may not be reduced immediately because the body is working hard to overcome the viral load. Depending on the disease’s progression this make take a while. I dislike such inexact terms like “awhile”. Does this mean 1 day or several hours? ( I am on vacation, more to follow in the next few days, stay tuned!)
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
